At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 76 enrolled
Drug / intervention
sufentanil sublingual 30 mcg tabletdrug
Likely dose
sufentanil sublingual 30 mcg tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for the Treatment of Acute Pain in Patients in Emergency Room Setting
In Brief
A Phase 3 clinical trial evaluating sufentanil sublingual 30 mcg tablet for Moderate-to-severe Acute Pain. Completed, enrolled 76 participants across 3 sites.
Detailed Summary
To evaluate the safety and efficacy of sufentanil tablet (ST) 30 mcg in the management of moderate-to-severe acute pain in patients in an emergency room (ER) setting.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate-to-severe Acute Pain
CountriesUnited States
CollaboratorsU.S. Army Medical Research and Development Command
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartOct 2015
Primary CompletionJun 2016
Study CompletionJul 2016
TodayJul 2026
First PostedMay 19, 2015
Enrollment StartOct 1, 2015
Primary CompletionJun 1, 2016
Study CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.1 years ago
Interventions
sufentanil sublingual 30 mcg tabletdrug